Publish date:

Wednesday's Late Winners & Losers

Countrywide soared after Bank of America's big investment.

The financial sector delivered a huge postclose winner in

Countrywide

(CFC)

Wednesday, as stocks from a variety of sectors came up mixed.

Countrywide shares vaulted 20.3% after

The Wall Street Journal

reported that

Bank of America

(BAC) - Get Bank of America Corp Report

is

preparing to invest $2 billion in the nation's biggest lender, which has struggled amid

bankruptcy fears after

drawing down its credit line last week. Countrywide shares were soaring $4.43 to $26.25 in recent extended trading. Bank of America added 95 cents, or 1.8%, to $52.60.

Also climbing after hours was

JDS Uniphase

(JDSU)

TheStreet Recommends

, a maker of communications-test and measurement products. The California-based company saw a

sequential profit rise to $15 million, or 7 cents an adjusted share in the fiscal fourth quarter. Thomson Financial's estimates had called for just 4 cents a share. JDS stock was up 2.7% to $14.75.

On the other hand, fellow tech name

Intuit

(INTU) - Get Intuit Inc. (INTU) Report

was trading lower before recently leveling out at $28.94 on word CEO Steve Bennett will resign at the end of the year. He will be replaced by senior VP Brad Smith. The company, which makes QuickBooks accounting and other financial-management software, also posted a narrower-than-expected fiscal fourth-quarter loss while guiding below next-quarter revenue estimates.

Seattle biotech

ZymoGenetics

(ZGEN)

also was coming back after trading lower. The stock was down just 3 cents -- after trading near 10% lower -- after the Food and Drug Administration determined that its submission of additional manufacturing-related information on its rThrombin product constitutes a "major amendment" to its biologics license application.

That extends the FDA's expected completion of the review by 3 months, to Jan. 17, which accordingly pushes back any future revenue from the product as well as a $40 million milestone payment under a license agreement with

Bayer

. The latter item should reduce 2007 revenue from that contract to some $3 million, vs. the previously expected $5 million to $8 million. Zymo shares were down 0.2% to $13.25 in recent after-hours trading.

And

Zumiez

(ZUMZ) - Get Zumiez Inc. Report

lost some of its intense regular-session run-up gains, even though the retailer of sports apparel and equipment nearly doubled its income year over year to 11 cents a share -- 3 cents past the Wall Street consensus. The Everett, Wash.-based company also saw sharply higher revenue to $82 million and padded its 2007 earnings forecast by 3 cents for a new range of between 97 cents and 99 cents a share. Still, shares retreated 1.4% at $47.24.